Skip to content
ModernDocHealth
Contact

Skip to section

Pediatrics

What the Latest Research Reveals

Data last updated: 31 studies cited

How this page is produced

Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This page is AI-generated and has not yet been reviewed by a clinician — it is not medical advice. Read how we build and check these pages.

91%
Reduction in MIS-C risk with vaccination
— protecting children from severe complications
Source: Zambrano et al.. MMWR (2022). 10.15585/mmwr.mm7102e1 | n=12000

KEY FINDINGS

Cardiac Involvement in MIS-C
80-90%
95% CI: 95% CI: 75-95%
Source [6]
Pediatric Long COVID (>12 weeks)
2-8%
95% CI: 95% CI: 1-12%
Source [8]
Preterm Birth Risk (Maternal COVID)
+50-80%
95% CI: OR 1.5-1.8 (95% CI: 1.3-2.1)
Source [11]
Vaccine Efficacy vs. Hospitalization
>90%
95% CI: 95% CI: 85-95%
Source [12]
Functional impairment documented among children with COVID-19 infection
21%
Source [31] · DOI ·
School decline in children with long COVID vs. infected children without long COVID
OR 3.5
95% CI: 95% CI 1.6-7.9
Source [31] · DOI ·
School support needs in children with long COVID
OR 2.4
95% CI: 95% CI 1.2-5.0
Source [31] · DOI ·
New or worsening behavioral or mental health symptoms in children with long COVID
OR 4.6
95% CI: 95% CI 2.1-9.2
Source [31] · DOI ·

THE TIMELINE

Acute Phase

0-4 weeks

Viral shedding peak days 1-7; GI symptoms more prominent than in adults

Key Event
Upper respiratory symptoms predominate

MIS-C Incidence (per 100,000 infections)

Source: Holm et al., Lancet Child Adolesc Health 2024; CDC surveillance

Cumulative Risk with Reinfection

1 infection+Baseline risk
2 infections+Additive risk
3+ infections+Under investigation

“Each infection carries risk of complications; cumulative organ damage possible”

THE HOPEFUL HORIZON

  • Vaccination reduces MIS-C by 91% and hospitalization by >90%[12]
  • Ventricular function normalizes in >90% of MIS-C cases within 1-4 weeks with treatment[13]
  • Omicron era showed >90% reduction in MIS-C incidence compared to pre-Omicron strains[6]
  • IVIG + corticosteroids reduces MIS-C treatment failure (OR 0.25, 95% CI 0.09-0.70)[15]

SOURCES

  1. [1]Bhopal SS, Bagaria J, Olabi B, Bhopal R. Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc Health. 2021;5(5):e12-e13. DOI (opens in new tab)
  2. [2]CDC COVID-NET: Coronavirus Disease 2019-Associated Hospitalization Surveillance Network. 2020-2024. DOI (opens in new tab)
  3. [3]Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. MMWR Morb Mortal Wkly Rep. 2021;70(49):1710-1716. DOI (opens in new tab)
  4. [4]Holm M, Espenhain L, Glenthoj J, et al. Risk and phenotype of multisystem inflammatory syndrome in vaccinated and unvaccinated Danish children before and during the Omicron wave. Lancet Child Adolesc Health. 2022;6(7):463-472. DOI (opens in new tab)
  5. [5]Hippich M, Holthaus L, Assfalg R, et al. A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. Med (N Y). 2021;2(2):149-163.e4. DOI (opens in new tab)

See a problem with the Pediatrics research summary?

Send a source correction or freshness concern. We cannot provide personal medical advice through this site.

Report a correction

SHARE THIS INFORMATION

Share with someone who needs to know

Back to DashboardReport an Issue

Data last updated:

Medical review: AI-generated — pending clinician review

Sources cited: 31 peer-reviewed sources

Claim verification: 0/0 verified (NaN%)

About DOIs

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for medical decisions. Data is sourced from peer-reviewed publications and may be updated as new research emerges.